P2‐113: Relationship between MRI findings, medical background and response to cerebrolysin in Alzheimer's disease patients: results from the Argentinean Cerebrolysin Registry

Several studies have demonstrated controversial relationship between vascular risk factors and MRI findings in Alzheimer Disease (AD) patients. The aim of this study is to evaluate if there are differences in AD patients with and without vascular risk factors (VRF) regarding MRI findings and response to cerebrolysin treatment. Design: Observation study. Clinicians that treated at least 5 patients with the drug were invited to voluntary participate. Inclusion criteria: AD or mixed dementia (MD) diagnosis according DSM IV. Data collected: age, sex, comorbidities, general and specific medication, MRI findings, MMS after and before, clinician's global impression (CGI) and adverse reactions. Statistical analysis: Wilcoxon test for paired or independent samples for discrete variables, Student T test for continuous variables, Chi squared test for discrete variables. Eleven clinicians sent information of 226 patients, 24 were excluded. Age 75.13 ± 7.40 yo, 50% females, AD 68%, MD 32%. VRF: arterial hypertension (AH) (n = 109), myocardial infarction (MI) (n = 29), diabetes (D) (n = 32), associations (n = 66). No VRF (n = 93). No differences regarding age, more males in MI (p < 0.01). Differences: leukoaraiosis and AH (p < 0.01 OR 4.45), MI (p < 0.01 OR 7.31), D (OR 6.83), multiple infarction: MI ((p < 0.01 OR 5.31), WMH: p < 0.01 for all VRF, Hypocampal atrophy and normal MRI p < 0.01 for no VRF (except against AH p 0.95 and 0.40). No microbleeds were reported. There were no differences between MMS pre and post treatment, in MMS absolute difference (AH 2.74, MI 2.39, D 2.23 NVRF 2.72) as well as in the improvement domains’ (cognitive, behavior or activities of daily life) between both groups. Our original contribution is that VRF are associated with ischemic lesions in MRI, specially in leukoaraiosis (OR > 4). Multiple infarction is associated with MI (OR5.31). Cerebrolysin's treatment showed efficacy in both VRF and NVRF patients.